BioXcel Therapeutics, Inc.

NasdaqCM:BTAI Stock Report

Market Cap: US$19.1m

BioXcel Therapeutics Management

Management criteria checks 2/4

BioXcel Therapeutics' CEO is Vimal Mehta, appointed in May 2017, has a tenure of 7.67 years. total yearly compensation is $4.73M, comprised of 21.2% salary and 78.8% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $23.75K. The average tenure of the management team and the board of directors is 7.5 years and 6.5 years respectively.

Key information

Vimal Mehta

Chief executive officer

US$4.7m

Total compensation

CEO salary percentage21.2%
CEO tenure7.7yrs
CEO ownership0.1%
Management average tenure7.5yrs
Board average tenure6.5yrs

Recent management updates

Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

Jun 04
Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

Recent updates

Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

Jun 04
Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

CEO Compensation Analysis

How has Vimal Mehta's remuneration changed compared to BioXcel Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$71m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$153m

Dec 31 2023US$5mUS$1m

-US$179m

Sep 30 2023n/an/a

-US$212m

Jun 30 2023n/an/a

-US$203m

Mar 31 2023n/an/a

-US$187m

Dec 31 2022US$5mUS$944k

-US$166m

Sep 30 2022n/an/a

-US$137m

Jun 30 2022n/an/a

-US$122m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021US$9mUS$917k

-US$107m

Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$100m

Mar 31 2021n/an/a

-US$94m

Dec 31 2020US$10mUS$890k

-US$82m

Sep 30 2020n/an/a

-US$69m

Jun 30 2020n/an/a

-US$54m

Mar 31 2020n/an/a

-US$41m

Dec 31 2019US$2mUS$459k

-US$33m

Sep 30 2019n/an/a

-US$32m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$22m

Dec 31 2018US$702kUS$423k

-US$19m

Compensation vs Market: Vimal's total compensation ($USD4.73M) is above average for companies of similar size in the US market ($USD645.47K).

Compensation vs Earnings: Vimal's compensation has increased whilst the company is unprofitable.

CEO

Vimal Mehta (62 yo)

7.7yrs

Tenure

US$4,731,147

Compensation

Dr. Vimal D. Mehta, Ph D., is Co-Founder of BioXcel Corporation and following its inception in 2005, has served as its Chairman and Chief Executive Officer. Dr. Mehta served as a Director at Invea Therapeu...

Leadership Team

NamePositionTenureCompensationOwnership
Vimal Mehta
Founder7.7yrsUS$4.73m0.12%
$ 23.7k
Javier Rodriguez
Senior VP4yrsUS$1.12m0.049%
$ 9.4k
Richard Steinhart
Senior VP & CFO7.3yrsUS$404.00k0.042%
$ 8.1k
Frank Yocca
Senior VP & Chief Scientific Officer7.6yrsUS$1.15m0.058%
$ 11.2k
Vincent O'Neill
Executive VP and Chief of Product Development & Medical Officer7.5yrsUS$510.17k0.040%
$ 7.7k

7.5yrs

Average Tenure

62yo

Average Age

Experienced Management: BTAI's management team is seasoned and experienced (7.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Vimal Mehta
Founder7.8yrsUS$4.73m0.12%
$ 23.7k
Steven Paul
Member of Advisory Boardno datano datano data
Peter Mueller
Independent Chairman & Lead Director7.8yrsUS$367.33k0.42%
$ 80.9k
Alan Breier
Member of Clinical Advisory Board6.5yrsno datano data
Thomas Laughren
Member of Clinical Advisory Board5.9yrsno datano data
Maurizio Fava
Member of Clinical Advisory Board5.9yrsno datano data
Stephen Marder
Member of Clinical Advisory Board6.5yrsno datano data
Sheldon Preskorn
Member of Clinical Advisory Board6.5yrsno datano data
John Krystal
Member of Clinical Advisory Board5.9yrsno datano data
Sandeep Laumas
Independent Director7.3yrsUS$329.83k0%
$ 0
Sheila Gujrathi
Member of Advisory Boardno datano datano data
George Grossberg
Member of Clinical Advisory Board6.5yrsno datano data

6.5yrs

Average Tenure

62yo

Average Age

Experienced Board: BTAI's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 08:09
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioXcel Therapeutics, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Guyn KimBMO Capital Markets Equity Research
Alec StranahanBofA Global Research